Trials / Unknown
UnknownNCT05808582
Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer
Multicenter, Single-arm, Open Clinical Study of Chidamide in Combination With Fulvestrant in HR+/HER2-advanced Breast Cancer That Has Failed Prior CDK4/6 Inhibitor Combined With Aromatase Inhibitor Therapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
evaluate the efficacy and safety of chidamide combined with fulvestrant for HR+ABC
Detailed description
This trial is a single-arm study. Designed to evaluate the efficacy and safety of chidamide combined with fulvestrant for HR+/HER2- advanced breast cancer that has failed previous CDK4/6 inhibitor combined with aromatase inhibitor therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | chidamide，fulvestrant | chidamide combined with fulvestrant |
Timeline
- Start date
- 2023-05-01
- Primary completion
- 2023-09-01
- Completion
- 2024-09-01
- First posted
- 2023-04-11
- Last updated
- 2023-04-14
Source: ClinicalTrials.gov record NCT05808582. Inclusion in this directory is not an endorsement.